Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Biophysical and biochemical properties of PHGDH revealed by studies on PHGDH inhibitors.

Cellular and molecular life sciences : CMLS - 31 Dec 2021

Tan Yuping, Zhou Xia, Gong Yanqiu, Gou Kun, Luo Youfu, Jia Da, Dai Lunzhi, Zhao Yinglan, Sun Qingxiang

Abstract excerpt

The rate-limiting serine biogenesis enzyme PHGDH is overexpressed in cancers. Both serine withdrawal and genetic/pharmacological inhibition of PHGDH have demonstrated promising tumor-suppressing activities. However, the enzyme properties of PHGDH are not well understood and the discovery of PHGDH inhibitors is still in its infancy. Here, oridonin was identified from a natural product library as a new PHGDH...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biological Products
Share to Biophysical Phenomena

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cysteine

Share to Enzyme Inhibitors

Share to Proteasome Endopeptidase Complex

Share to Protein Aggregates

Share to Proteolysis

Source

Open in PubMed Open full text

Identifiers

PMID: 34971423
DOI: 10.1007/s00018-021-04022-2
PMCID: PMC11073335

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Biophysical and biochemical properties of PHGDH revealed by studies on PHGDH inhibitors.PMID 34971423Read ↗

Wild-Type IDH Enzymes as Actionable Targets for Cancer TherapySemantic proximity Read ↗

Targeting both the enzymatic and non-enzymatic functions of DHODH as a therapeutic vulnerability in c-Myc-driven cancerSemantic proximity Read ↗

Structure-Based Survey of the Human Proteome for Opportunities in Proximity PharmacologySemantic proximity Read ↗

DPH1 and DPH2 variants that confer susceptibility to diphthamide deficiency syndrome in human cells and yeast models.Semantic proximity Read ↗

Current Status of the Use of Multifunctional Enzymes as Anti-Cancer Drug TargetsSemantic proximity Read ↗

Crystal structures of pan-IDH inhibitor AG-881 in complex with mutant human IDH1 and IDH2.Semantic proximity Read ↗

Functional Integrity of Radical SAM Enzyme Dph1•Dph2 Requires Non-canonical Cofactor Motifs with Tandem CysteinesSemantic proximity Read ↗

Rational Computational Approaches in Drug Discovery: Potential Inhibitors for Allosteric Regulation of Mutant Isocitrate Dehydrogenase-1 Enzyme in Cancers.Semantic proximity Read ↗

POH1/Rpn11/PSMD14: a journey from basic research in fission yeast to a prognostic marker and a druggable target in cancer cellsSemantic proximity Read ↗

Discovery and characterisation of the automethylation properties of PRDM9.Semantic proximity Read ↗

PHGDH Acts as an Oncogenic Accelerator by Activating the c-MYC/CDK2 Axis to Drive Cell Cycle Progression in Endometrial CancerSemantic proximity Read ↗

A novel allosteric site employs a conserved inhibition mechanism in human kidney-type glutaminase.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.